top of page
Latest Updates
May 13, 2025
Numiera Therapeutics CEO Dr. Izi Stoll is awarded best startup pitch at the BioNJ partnering meeting at Liberty Science Center in Jersey City NJ.
Apr 3, 2025
Numiera Therapeutics CEO Dr. Izi Stoll announces the company's upcoming seed financing round at Venture Summit West in Mountain View CA.
Mar 30, 2025
Numiera Therapeutics announces it has hired Dr. Megan Halloran to support communications between the company and its stakeholders.
Feb 21, 2025
Numiera Therapeutics announces its investors receive a tax incentive from Colorado's Office of Economic Development and International Trade.
Jan 10, 2025
Numiera Therapeutics announces it has been granted Orphan Drug Designation to use etomoxir in the treatment of patients with malignant glioma.
Nov 21, 2024
Numiera Therapeutics announces its competitively-awarded grant from Colorado's Office of Economic Development and International Trade.
Aug 21, 2024
Numiera Therapeutics announces a significant expansion of the leadership team to include pharma experts Gordon Beck and Karl Nicholls.
Patient Advocacy
GBM5 Drug Development Summit
Meeting with the team at End Brain Cancer 2024
Research Recognition
Society for Neuro Oncology
Translational Research Award 2016
bottom of page